Änderungen im Programmablauf vorbehalten.
|Saal 3||16:15 - 17:45||03.10.2015|
|Optic Neuritis and Multiple Sclerosis: State of the Art Symposium der Sektion DOG-Neuro-Ophthalmologie|
Vorsitzende/r: Helmut Wilhelm (Tübingen), Klaus Rüther (Berlin)
Treatment options for Multiple Sclerosis have changed dramatically during the last years. It is essential for the ophthalmologist to be aware of diagnostic requirements and therapeutic approaches in optic neuritis. This symposium will discuss the following questions: How to distinguish different types of optic neuritis? How much diagnostics do we need? Which kind of therapy can we offer to whom?
Referent/in: Helmut Wilhelm (Tübingen)
Optic neuritis is a clinical diagnosis based on history and ophthalmological examination. However, the ophthalmologist has to make sure that both history and findings are compatible. He has to be aware of hints on atypical manifestations like neuroretinitis, neuromyelitis optica or chronic relapsing inflammatory optic neuropathy that might require additional diagnostic tests and different therapy.
Referent/in: Jonathan Trobe (Ann Arbor)
In the past, the approach to the patient with optic neuritis was dominated by the results of the multicenter Optic Neuritis Treatment Trial, which indicated that treatment with corticosteroids was basically ineffective. The available prophylactic medications (interferons and glatiramer), used to reduce the pace of multiple sclerosis, were only marginally effective, so physicians were hesitant to prescribe them for optic neuritis alone, especially because so many patients had a benign natural course. Things are more complicated now. The newer oral prophylactic agents and natalizumab seem to be more effective. Also, the discovery of the aquaporin antibody as a marker for neuromyelitis optica has forced ophthalmologists to consider this diagnosis.
Referent/in: Mathias Mäurer (Bad Mergentheim)
Optic neuritis is a common primary manifestation of multiple sclerosis (MS). To determine if a patient with optic neuritis has a risk for further neurological symptoms and therefore a risk to develop MS in the future it necessary to look for signs and symptoms of a disseminated neurological disease. Therefore MRI findings are of paramount importance. In case of an abnormal MRI the risk to develop MS is around 90% within the next decade. Therefore a sophisticated immunomodulatory treatment is often indicated in patients with optic neuritis and abnormal MRI findings.
Referent/in: Wolf Lagrèze (Freiburg)
This talk will cover preclinical as well as current clinical research on neuroprotection in optic neuritis and MS as a new therapeutic concept in addition to existing immunomodulatory therapies.